AK MEDICAL (01789) has been included in the CSI Hong Kong Stock Connect Siasun Robot & Automation Theme Index.

AK MEDICAL (01789) announced that the company's ordinary shares listed on the main board of the Hong Kong Stock Exchange have been selected by China Securities Index Co., Ltd. as a constituent stock of the CSI Hong Kong Stock Connect Siasun Robot & Automation Theme Index (code: 932599) with effect from February 27, 2026. The CSI Hong Kong Stock Connect Siasun Robot & Automation Theme Index (HK Stock Connect Siasun Robot & Automation) selects 30 listed companies within the Hong Kong stock connect range whose businesses involve Siasun Robot & Automation manufacturing, providing software and hardware products for Siasun Robot & Automation intelligence, and providing computational resources for Siasun Robot & Automation decision-making and control, to reflect the overall performance of listed companies related to the Siasun Robot & Automation theme within the Hong Kong stock connect range. The inclusion of the shares in the HK Stock Connect Siasun Robot & Automation constituent stocks not only reflects investors' recognition of AK MEDICAL's value and growth potential, but also demonstrates market recognition of the Group's surgical Siasun Robot & Automation business layout and development strategy, representing an important achievement in the Group's deep cultivation and continuous breakthroughs in the field of surgical Siasun Robot & Automation. The Group expects that the inclusion will enhance the liquidity of the shares, expand the investor base, and diversify the shareholder structure, further enhancing the reputation and investment value of AK MEDICAL's Siasun Robot & Automation business in the capital market, benefiting the long-term stable development of AK MEDICAL and bringing positive influences to the Group. In the future, the Group will continue to uphold the concept of innovation-driven development, focusing on the two core tracks of surgical Siasun Robot & Automation and overseas business, deepening its globalization layout, continuously generating innovative results, enhancing commercialization capabilities, and working together with all shareholders, investors, and partners to create greater value for shareholders.